HSV-1-derived amplicon vectors: Recent technological improvements and remaining difficulties - A Review

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 3, 2009, Pages 399-410

  Epstein, Alberto Luis ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Viral vectors HSV 1 based amplicons applications technological improvements

Indexed keywords

HUMAN HERPESVIRUS 1;

EID: 67649540522     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000300002     Document Type: Review

References (84)

1. Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO 2003. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Ther 10: 1691-1702.
2. Boehmer PE, Lehman IR 1997. Herpes simplex virus DNA replication. Annu Rev Biochem 66: 347-384.
3. Boutell C, Canning M, Orr A, Everett RD 2005. Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol 79: 12342-12354.
4. Bowers WJ, Mastrangelo MA, Howard DF, Southerland HA, Maguire-Zeiss KA, Federoff HJ 2006. Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther 13: 580-588.
5. Brockman MA, Knipe DM 2002. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 76: 3678-3687.
6. Brooks AI, Cory-Slechta DA, Bowers WJ, Murg SL, Federoff HJ 2000. Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. Hum Gene Ther 11: 2341-2352.
7. Burris CA, de Silva S, Narrow WC, Casey AE, Lotta LT Jr, Federoff HJ, Bowers WJ 2008. Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0. J Gene Med 10: 152-164.
8. Chelbi-Alix MK, De The H 1999. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18: 935-941.
9. Cuchet D, Potel C, Thomas J, Epstein AL 2007. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther 7: 975-995.
10. Cunningham C, Davison AJ 1993. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 197: 116-124.
11. Deiss LP, Chou J, Frenkel N 1986. Functional domains within the a sequence involved in the cleavage-packaging of herpes simplex virus DNA. J Virol 59: 605-618.
12. During MJ, Naegele JR, O'Malley KL, Geller AI 1994. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266: 1399-1403.
13. Everett RD, Boutell C, Orr A 2004. Phenotype of a herpes simplex virus type 1 mutant that fails to express immediate-early regulatory protein ICP0. J Virol 78: 1763-1774.
14. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 80: 7995-8005.
15. Fotaki ME, Pink JR, Mous J 1997. Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer. Gene Ther 4: 901-908.
16. Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA 1997. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med 3: 813-825.
17. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI 1996. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 70: 7190-7197.
18. Geller AI 1988. A new method to propagate defective HSV-1 vectors. Nucleic Acids Res 16: 5690.
19. Geller AI, Keyomarsi K, Bryan J, Pardee AB 1990. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 87: 8950-8954.
20. Glauser DL, Ackermann M, Saydam O, FraefeL C 2006. Chimeric herpes simplex virus/adeno-associated virus amplicon vectors. Curr Gene Ther 6: 315-324.
21. Glauser DL, Saydam O, Balsiger NA, Heid I, Linden RM, Ackermann M, Fraefel C 2005. Four-dimensional visualization of the simultaneous activity of alternative adeno-associated virus replication origins. J Virol 79: 12218-12230.
22. Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, Lim F, Wade-Martins R 2007. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells. Mol Ther 15: 248-254.
23. Gu H, Roizman B 2003. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a. Proc Natl Acad Sci USA 100: 8963-8968.
24. Heilbronn R, Burkle A, Stephan S, Zur Hausen H 1990. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J Virol 64: 3012-3018.
25. Heister T, Heid I, Ackermann M, Fraefel C 2002. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate sitespecific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J Virol 76: 7163-7173.
26. Hibbitt OC, Wade-Martins R 2006. Delivery of large genomic DNA inserts > 100 kb using HSV-1 amplicons. Curr Gene Ther 6: 325-336.
27. Ho DY, Mc Laughlin JR, Sapolsky RM 1996. Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system. Brain Res Mol Brain Res 41: 200-209.
28. Ho DY, Mocarski ES, Sapolsky RM 1993. Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc Natl Acad Sci USA 90: 3655-3659.
29. Hocknell PK, Wiley RD, Wang X, Evans TG, Bowers WJ, Hanke T, Federoff HJ, Dewhurst S 2002. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific and durable cellular and humoral immune responses. J Virol 76: 5565-5580.
30. Hong Z, Ferrari E, Wright-Minogue J, Chase R, Risano C, Seelig G, Lee CG, Kwong AD 1996. Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol 70: 4261-4268.
31. Horsburgh BC, Hubinette MM, Qiang D, MacDonald ML, Tufaro F 1999. Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes. Gene Ther 6: 922-930.
32. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z 1997. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91: 501-510.
33. Jeong KH, Bakowska JC, Song IO, Fu N, Brakefield XO, Kaiser UB 2007. Improvement in reproductive parameters in hypogonadal female mice by regulated gene replacement therapy in the central nervous system. Gene Ther 14: 1092-1101.
34. Jerusalinsky D, Epstein AL 2006. Amplicon vectors as outstanding tools to study and modify cognitive functions. Curr Gene Ther 6: 351-360.
35. Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO 1997. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 8: 359-370.
36. Kalamvoki M, Mavromara P 2004. Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein. J Virol 78: 11865-11878.
37. Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DW 1994. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA 91: 8979-8983.
38. Kwong AD, Frenkel N 1984. Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eucaryotic DNA sequences. J Virol 51: 595-603.
39. Lam P, Hui KM, Wang Y, Allen PD, Louis DN, Yuan CJ, Breakefield XO 2002. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 13: 2147-2159.
40. Larin Z, Mejia JE 2002. Advances in human artificial chromosome technology. Trends Genet 18: 313-319.
41. Lauterbach H, Ried C, Epstein AL, Marconi P, Brocker T 2005. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J Gen Virol 86: 2401-2410.
42. Lim F, Hartley D, Starr P, Lang P, Song S, Yu L, Wang Y, Geller AI 1996. Generation of high-titer defective HSV-1 vectors using an IE 2 deletion mutant and quantitative study of expression in cultured cortical cells. Biotechniques 20: 460-469.
43. Liu Q, Perez CF, Wang Y 2006. Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector. J Virol 80: 1672-1679.
44. Logvinoff C, Epstein AL 2000. Genetic engineering of herpes simplex virus and vector genomes carrying loxP sites in cells expressing Cre recombinase. Virology 267: 102-110.
45. Lu B, Federoff HJ 1995. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression. Hum Gene Ther 6: 419-428.
46. Lufino MM, Edser PA, Wade-Martins R 2008. Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery and transgene expression. Mol Ther 16: 1525-1538.
47. Lufino MM, Manservigi R, Wade-Martins R 2007. An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. NAR 35: e98.
48. Moralli D, Simpson KM, Wade-Martins R, Monaco ZL 2006. A novel human artificial chromosome gene expression system using herpes simplex virus type 1 vectors. EMBO Rep 7: 911-918.
49. Mossman KL, MacGregor PF, Rozmus JJ, Goryachev AB, Edwrds AM, Smiley JR 2001. Herpes simplex virus triggers and then disarms a host antiviral response. J Virol 75: 750-758.
50. Mossman KL, Smiley JR 2002. Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J Virol 76: 1995-1998.
51. Muller L, Saydam O, Saeki Y, Heid I, Fraefel C 2005. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol Methods 123: 65-72.
52. Parrish E, Peltékian E, Dickson G, Epstein AL, Garcia L 1999. Cell engineering for muscle gene therapy: extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes. Cytotechnology 30: 173-180.
53. Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO 1996. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther 7: 2003-2013.
54. Rasmussen M, Kong L, Zhang GR, Liu M, Wang X, Szabo G, Curthoys NP, Geller AI 2007. Glutamatergic or GABAergic neuron-specific, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter. Brain Res 1144: 19-32.
55. Saeki Y, Breakefield XO, Chiocca EA 2003. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 76: 51-60.
56. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA 2001. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3: 591-601.
57. Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C 1998. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 9: 2787-2794.
58. Samady L, Costigliola E, MacCormac L, McGrath Y, Cleverley S, Lilley CE, Smith J, Latchman DS, Chain B, Coffin RS 2003. Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs-HSV vectors for dendritic cell-mediated immunotherapy. J Virol 77: 3768-3776.
59. Santos K, Duke CMP, Dewhurst S 2006. Amplicons as vaccine vectors. Curr Gene Ther 6: 383-392.
60. Savard N, Cosset FL, Epstein AL 1997. Defective herpes simplex virus type 1 vectors harboring gag, pol and env genes can be used to rescue defective retrovirus vectors. J Virol 71: 4111-4117.
61. Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO 1999. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol 73: 10426-10439.
62. Shah K, Breakefield XO 2006. HSV amplicon vectors for cancer therapy. Curr Gene Ther 6: 361-370.
63. Song S, Wang Y, Bak SY, Lang P, Ullrey D, Neve RL, O'Malley KL, Geller AI 1997. An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J Neurochem 68: 1792-1803.
64. Spaete RR, Frenkel N 1982. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30: 295-304.
65. Spaete RR, Frenkel N 1985. The herpes simplex virus amplicon: analyses of cis-acting replication functions. Proc Natl Acad Sci USA 82: 694-698.
66. Stavropoulos TA, Strathdee CA 1998. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 72: 7137-7143.
67. Suzuki M, Chiocca EA, Saeki Y 2007. Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther 15: 2017-2026.
68. Suzuki M, Chiocca EA, Saeki Y 2008. Stable transgene expression from HSV amplicon vectors in the brain: potential involvement of immunoregulatory signals. Mol Ther 16: 1727-1736.
69. Suzuki M, Kasai K, Saeki Y 2006. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol 80: 3293-3300.
70. Tsimbouri P, Drotar ME, Coy JL, Wilson JB 2002. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene 21: 5182-5187.
71. Tsitoura E, Georgopoulou U, Mavromara P 2006. HSV-1 based amplicon vectors as an alternative system for the expression of functional HCV proteins. Curr Gene Ther 6: 393-398.
72. Tsitoura E, Lucas M, Revol-Guyot V, Epstein AL, Manservigi R, Mavromara P 2002. Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. J Gen Virol 83: 561-566.
73. Tyler CM, Wuertzer CA, Bowers WJ, Federoff HJ 2006. HSV amplicons: neuro applications. Curr Gene Ther 6: 337-350.
74. Vlazny DA, Frenkel N 1981. Replication of herpes simplex virus DNA: localization of replication recognition signals within defective virus genomes. Proc Natl Acad Sci USA 78: 742-746.
75. Wade-Martins R, Saeki Y, Chiocca EA 2003. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 7: 604-612.
76. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y 2001. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 19: 1067-1070.
77. Wang S, Di S, Young WB, Jacobson C, Link CJ Jr 1997. A novel herpesvirus amplicon system for in vivo gene delivery. Gene Ther 4: 1132-1141.
78. Wang S, Petravicz J, Breakefield XO 2003. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol Ther 7: 790-800.
79. Wang S, Vos JM 1996. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 70: 8422-843
80. Wang Y, Camp SM, Niwano M, Shen X, Bakowska JC, Breakefield XO, Allen PD 2002. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J Virol 76: 7150-7162.
81. Whitley RJ 2001. Herpes simplex viruses. In DM Knipe, PM Howley (eds.), Fields Virology, Lippincott Williams & Wilkins, Philadelphia, p. 2461-2510.
82. York IA, Roop C, Andrews DW, Riddell SR, Graham FL, Johnson DC 1994. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+T lymphocytes. Cell 77: 525-535.
83. Zaupa C, Revol-Guyot V, Epstein AL 2003. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther 14: 1049-1063.
84. Zhang X, O'Shea H, Entwisle C, Boursnell M, Efstathiou S, Inglis S 1998. An efficient selection system for packaging herpes simplex virus amplicons. J Gen Virol 79: 125-131.